Macroaxis Stories

Are Genelux (USA Stocks:GNLX) investors shifting to Intel (USA Stocks:INTC)?

February 24, 2023  By Ellen Johnson
Macroaxis Story
As many rational traders are trying to avoid healthcare space, it makes sense to break down Genelux Common a little further and understand how it stands against Intel and other similar entities. We are going to inspect some of the competitive aspects of both Genelux and Intel.
Published over a year ago
View all stories for Genelux Common | View All Stories

Reviewed by Vlad Skutelnik

By analyzing existing essential indicators between Genelux Common and Intel, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Intel with a short position in Genelux Common. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Genelux suggests not a very effective usage of assets in February.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Genelux Common. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its performance over time. Several factors influence the investment perspective on Genelux Common, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.

How does Genelux utilize its cash?

Genelux Common reported Total Cash From Operating Activities of (20.27 Million) in 2023. To perform a cash flow analysis of Genelux Common, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Genelux Common is receiving and how much cash it distributes out in a given period. The Genelux Common cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Genelux Common Gross Profit

Genelux Common Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Genelux Common previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Genelux Common Gross Profit growth over the last 10 years. Please check Genelux Common's gross profit and other fundamental indicators for more details.

Genelux Common Balance Sheet Drivers

Understanding current and past Genelux Common financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.
Details

An Additional Perspective On Genelux Common

Total Debt Breakdown

Let me now analyze Genelux Common total debt. Based on the latest financial disclosure, Genelux Common has a Total Debt of 18.02 M. This is 99.34% lower than that of the Healthcare sector and 94.45% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.66% higher than that of Genelux Common. As for Intel we see total debt of 37.68 B, which is much higher than that of the Biotechnology
INTC
37.7 B
GNLX18.02 Million0.0474
Sector324.78 Million0.85
INTC37.68 Billion99.1

Another 3 percent rise for Genelux Common

Current value at risk indicator falls down to -3.88. Possible price jump?
As of the 24th of February, Genelux Common retains the Risk Adjusted Performance of 0.3887, downside deviation of 3.06, and Market Risk Adjusted Performance of 33.15. Genelux Common technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Genelux Common, which can be compared to its competitors. Please check out Genelux Common coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Genelux Common is priced fairly, providing market reflects its last-minute price of 10.86 per share. Given that Genelux Common has jensen alpha of 2.51, we strongly advise you to confirm Genelux Common's regular market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Genelux Common

While many other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Genelux Common may offer a potential longer-term growth to investors. To conclude, as of the 24th of February 2023, our analysis shows that Genelux Common barely shadows the market. The company is overvalued and projects low probability of distress for the next 2 years. However, our ongoing 90 days recommendation on the company is Strong Buy.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Genelux Common. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com